Physician profile
Christopher John Malinky
NPI 1669638144
$4,951.13
in general payments reported to CMS, 2019-2025
23 companies · $974 in 2025
The $974 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $282 · 2021: $97.57 · 2022: $293 · 2023: $1,065 · 2024: $1,250 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,014 · Consulting Fee: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,013.65 |
| Consulting Fee | $1,275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,842.95 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Tersera Therapeutics LLC | $354.98 | 2019-2025 | Prialt |
| Abbott Laboratories | $315.95 | 2019-2025 | Eterna, Proclaim, Ionicrf |
| Medtronic USA, INC. | $190.62 | 2019-2020 | |
| Si-Bone, INC. | $167.65 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $131.42 | 2019-2025 | Xtampza, Belbuca |
| Vertos Medical, INC. | $124.26 | 2019-2024 | Mild Device Kit |
| Painteq LLC | $123.46 | 2024 | Painteq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.07 | 2023-2025 | Relistor |
| Medtronic, INC. | $118.78 | 2021-2024 | Intellis Adaptivestim |
| Pfizer INC. | $76.12 | 2019-2024 | |
| Abbvie INC. | $65.11 | 2023-2024 | |
| Nalu Medical, INC. | $51.10 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.46 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.20 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $38.15 | 2019 | |
| Allergan, INC. | $28.99 | 2019 | |
| Nevro Corp. | $26.54 | 2024 | Senza |
| Sentynl Therapeutics, INC. | $26.17 | 2019 | |
| Ibsa Pharma INC. | $20.63 | 2024 | Licart, Flector, Tirosint |
| Vertex Pharmaceuticals Incorporated | $15.27 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.38 | 2021 | |
| Depuy Synthes Sales INC. | $13.87 | 2023 | Orthovisc, Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Malinky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.